Global Gout Therapeutics Market 2016-2020

痛風治療薬の世界市場2016-2020

◆タイトル:Global Gout Therapeutics Market 2016-2020
◆商品コード:IRTNTR10483
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年10月25日
◆ページ数:59
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、痛風治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、痛風治療薬の世界市場規模及び予測、種類別分析、薬剤種類別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

Gout is one type of arthritis, which is caused by the high levels of uric acid in the blood. The main symptoms of gout are sudden attack of burning pain, swelling in a joint, and stiffness, usually in toe. If it is not treated, over time, it can harm tendons, joints, and other tissues. NSAIDs and urate-lowering agents are preferred treatment options for gout.
Technavio’s analysts forecast the global gout therapeutics market to grow at a CAGR of 17.16% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global gout therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Gout Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• Horizon Pharma
• Takeda Pharmaceuticals

[Other prominent vendors]
• Ablynx
• Alder Biopharmaceuticals
• Antares Pharma
• Astellas Pharma
• Boehringer Ingelheim
• Can-Fite BioPharma
• Celgene
• Celltrion
• ChemoCentryx
• CymaBay Therapeutics
• Eisai
• Eli Lilly
• Gilead Sciences
• GlaxoSmithKline
• Incyte
• Ironwood Pharmaceuticals
• JW Pharmaceutical
• KaloBios Pharmaceuticals
• Lexicon Pharmaceuticals
• LG Life Sciences
• Merck
• Morphotek
• Novartis
• Novo Nordisk
• Regeneron Pharmaceuticals
• Sandoz
• Sanofi
• Santarus
• Selecta Biosciences
• Teijin Pharma
• UCB
• Vertex Pharmaceuticals.

[Market driver]
• Introduction of novel urate-lowering agents
• For a full, detailed list, view our report

[Market challenge]
• Low physician and patient awareness
• For a full, detailed list, view our report

[Market trend]
• Focus on regenerative medicines
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Gout: Disease overview

PART 06: Pipeline portfolio

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Key buying criteria

PART 09: Market segmentation by drug class
• NSAIDs
• Corticosteroids
• Colchicine
• Urate-lowering agents

PART 10: Market segmentation by type of disease

PART 11: Geographical segmentation
• Gout therapeutics market in Americas
• Gout therapeutics market in EMEA
• Gout therapeutics market in APAC
• Market overview

PART 12: Market drivers
• Introduction of novel urate-lowering agents
• Technological advancements in medical imaging
• Popularity of off-label and OTC drugs

PART 13: Impact of drivers

PART 14: Market challenges
• Low physician and patient awareness
• Heavy dependency on generic drugs
• Use of CAM for treatment of gout

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Focus on regenerative medicines
• High growth potential of biologics
• Preference for combination therapies

PART 17: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 18: Key vendor analysis
• AstraZeneca
• Horizon Pharma
• Takeda Pharmaceuticals

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global gout therapeutics market overview
Exhibit 03: Stages of gout
Exhibit 04: Mechanism of gout
Exhibit 05: Gout: overview
Exhibit 06: Treatment algorithm for gout
Exhibit 07: Pipeline analysis of major companies for global gout therapeutics market
Exhibit 08: Share of pipeline molecules in global gout therapeutics market
Exhibit 09: Few pipeline candidates under development in global gout therapeutics market:
Exhibit 10: Market snapshot: Global gout therapeutics market
Exhibit 11: Global statistics for gout in 2015
Exhibit 12: Correlation between serum uric acid concentration and cigarette smoking status
Exhibit 13: Factors influencing the global gout therapeutics market 2015
Exhibit 14: Global gout therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 15: Global gout therapeutics market 2015-2020 ($ billions)
Exhibit 16: Opportunities in gout arthritis industry today
Exhibit 17: Impact of drivers and challenges of global gout therapeutics market
Exhibit 18: Five forces analysis
Exhibit 19: Key buying criteria for gout therapeutics market
Exhibit 20: Key buying criteria for global gout therapeutics market 2015
Exhibit 21: Impact of key customer segments on global gout therapeutics market 2015
Exhibit 22: Market segmentation by drug class: Global gout therapeutics market
Exhibit 23: Common NSAIDs used for treatment of gout
Exhibit 24: Market segmentation by drug class: Present and future scenarios
Exhibit 25: Global gout therapeutics market: Segmentation by type 2015-2020
Exhibit 26: Global gout therapeutics market segmentation: Growth cycle analysis
Exhibit 27: Snapshot of global gout therapeutics market by segmentation
Exhibit 28: Snapshot of global gout therapeutics market by geography
Exhibit 29: Global gout therapeutics market revenue by geography 2015-2020 ($ millions)
Exhibit 30: Percentage share of global gout therapeutics market by geography 2015
Exhibit 31: Percentage share of global gout therapeutics market by geography 2020
Exhibit 32: Global gout therapeutics market: Country analysis based on revenue and growth rate
Exhibit 33: Gout therapeutics market in Americas 2015-2020 ($ millions)
Exhibit 34: Gout therapeutics market in EMEA 2015-2020 ($ millions)
Exhibit 35: Opportunity of RDEA3170 in APAC
Exhibit 36: Gout therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 37: Phase III clinical study data and future opportunities for urate-lowering agent – Zurampic (lesinurad)
Exhibit 38: Impact of drivers
Exhibit 39: Common CAM therapies used for gout treatment
Exhibit 40: Usage of CAM therapies in US adults 2015
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Impact of trends on global gout therapeutics market
Exhibit 43: Ranking of major vendors for global gout therapeutics market
Exhibit 44: Geographical presence of key vendors
Exhibit 45: Company portfolio analysis in global gout therapeutics market 2016-2020
Exhibit 46: AstraZeneca: Key highlights
Exhibit 47: AstraZeneca: Strength assessment
Exhibit 48: AstraZeneca: Strategy assessment
Exhibit 49: AstraZeneca: Opportunity assessment
Exhibit 50: Horizon Pharma: Key highlights
Exhibit 51: Horizon Pharma: Strength assessment
Exhibit 52: Horizon Pharma: Strategy assessment
Exhibit 53: Horizon Pharma: Opportunity assessment
Exhibit 54: Takeda Pharmaceuticals: Key highlights
Exhibit 55: Takeda Pharmaceuticals: Strength assessment
Exhibit 56: Takeda Pharmaceuticals: Strategy assessment
Exhibit 57: Takeda Pharmaceuticals: Opportunity assessment



【掲載企業】

AstraZeneca, Horizon Pharma, Takeda Pharmaceuticals, Ablynx, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, CymaBay Therapeutics, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, Ironwood Pharmaceuticals, JW Pharmaceutical, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, Merck, Morphotek, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Selecta Biosciences, Teijin Pharma, UCB, Vertex Pharmaceuticals.

【資料のキーワード】

痛風、痛風治療薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[痛風治療薬の世界市場2016-2020] (Global Gout Therapeutics Market 2016-2020 / IRTNTR10483)販売に関する免責事項
[痛風治療薬の世界市場2016-2020] (Global Gout Therapeutics Market 2016-2020 / IRTNTR10483)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆